The addition of the first-in-class direct lytic agent exebacase (lysin CF-301) to standard-of-care (SOC) antibiotics demonstrated efficacy against Staphylococcus aureus bacteraemia (SAB), particularly difficult-to-treat methicillin-resistant SA (MRSA), compared with SOC antibiotics alone, according to the results of a phase II trial presented at ECCMID 2019.
The novel human monoclonal antibody suvratoxumab yielded a trend toward reducing the incidence of Staphylococcus aureus pneumonia (SAP) in high-risk, mechanically-ventilated intensive care unit (MV ICU) patients with an acceptable safety profile, according to data from the phase II SAATELLITE* trial presented at ECCMID 2019.
The selective cap-dependent endonuclease inhibitor baloxavir marboxil (hereafter baloxavir) effectively improves influenza symptoms in adolescent patients and those at high risk for influenza complications, according to two subanalyses of the CAPSTONE studies presented at ECCMID 2019.
The novel pleuromutilin antibiotic lefamulin - now in an oral therapy form - has demonstrated a favourable safety and tolerability profile for community-acquired bacterial pneumonia (CABP) in the LEAP* 2 study, the same result seen for intravenous (IV) lefemulin in the original LEAP 1 study.
Many patients prescribed antibiotics for suspected urinary tract infection (UTI) in the emergency department (ED) may not actually require them, according to a single-centre study from the UK presented at ECCMID 2019.
The combination of the antipseudomonal cephalosporin, ceftolozane, and an extended-spectrum β-lactamase inhibitor, tazobactam (ceftolozane/tazobactam), is noninferior to meropenem in the treatment of adults with ventilated nosocomial pneumonia (VNP), phase 3 data from the ASPECT-NP* trial have shown.
Migraine and headache are common ailments of people living in the modern era. Dr Jon Marshall of The Singapore Headache and Migraine Clinic shares his insights with Pearl Toh on how to manage migraine and headache using non-pharmaceutical strategies, with a focus on the manual medicine approach.
The effect of cannabidiol (CBD) in the treatment of patients with Lennox–Gastaut syndrome may occur within 7 days of initiation, and most adverse events resolve within a 14-week period, a study reports.
In a webinar held on 27 March 2021, paediatric
endocrinology nurses Karen Blair,
Kate Davies, and Siti Zarina Yaakop shared
insights and clinical experience based
on their frontline roles in caring for patients
with central precocious puberty (CPP)
and supporting their family members.